Literature DB >> 20823286

Tolerance of benznidazole in treatment of Chagas' disease in adults.

María-Jesús Pinazo1, José Muñoz, Elizabeth Posada, Paulo López-Chejade, Montserrat Gállego, Edgar Ayala, Elena del Cacho, Dolors Soy, Joaquim Gascon.   

Abstract

Chagas' disease is an emerging public health problem in areas where the disease is not endemic. Treatment with benznidazole has shown efficacy in the acute stage of the disease, but its efficacy in the chronic stage remains controversial, and unwanted side effects are more frequent and severe in adults than in children. This study describes the profile of side effects of benznidazole in a cohort of Trypanosoma cruzi-infected patients in a European country.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20823286      PMCID： PMC2976114          DOI： 10.1128/AAC.00537-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up.

Authors:  C D Fernandes; F M Tiecher; M M Balbinot; D B Liarte; D Scholl; M Steindel; A Romanha
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-02       Impact factor: 2.743

2.  Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

Authors:  Jose Antonio Marin-Neto; Anis Rassi; Carlos A Morillo; Alvaro Avezum; Stuart J Connolly; Sergio Sosa-Estani; Fernando Rosas; Salim Yusuf
Journal:  Am Heart J       Date:  2008-07       Impact factor: 4.749

3.  [Use of thioctic acid for prevention of the adverse effects induced by benznidazole in patients with chronic Chagas' infection].

Authors:  D J Carpintero
Journal:  Medicina (B Aires)       Date:  1983       Impact factor: 0.653

4.  Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.

Authors:  Rodolfo Viotti; Carlos Vigliano; Bruno Lococo; Graciela Bertocchi; Marcos Petti; María Gabriela Alvarez; Miriam Postan; Alejandro Armenti
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

Review 5.  Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina.

Authors:  Sergio Sosa-Estani; Elsa Leonor Segura
Journal:  Curr Opin Infect Dis       Date:  2006-12       Impact factor: 4.915

6.  Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease.

Authors:  S Sosa Estani; E L Segura; A M Ruiz; E Velazquez; B M Porcel; C Yampotis
Journal:  Am J Trop Med Hyg       Date:  1998-10       Impact factor: 2.345

7.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

8.  Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution.

Authors:  Diana L Fabbro; Mirtha L Streiger; Enrique D Arias; María L Bizai; Mónica del Barco; Norberto A Amicone
Journal:  Rev Soc Bras Med Trop       Date:  2007 Jan-Feb       Impact factor: 1.581

9.  Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples.

Authors:  Maria Piron; Roser Fisa; Natalia Casamitjana; Paulo López-Chejade; Lluís Puig; Mireia Vergés; Joaquim Gascón; Jordi Gómez i Prat; Montserrat Portús; Sílvia Sauleda
Journal:  Acta Trop       Date:  2007-06-23       Impact factor: 3.112

Review 10.  Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.

Authors:  Rodolfo Viotti; Carlos Vigliano; Bruno Lococo; Maria Gabriela Alvarez; Marcos Petti; Graciela Bertocchi; Alejandro Armenti
Journal:  Expert Rev Anti Infect Ther       Date:  2009-03       Impact factor: 5.091
View more
  59 in total

1.  Clinical aspects of Chagas disease and implications for novel therapies.

Authors:  Cristiane Menezes; Germano Carneiro Costa; Kenneth J Gollob; Walderez O Dutra
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  Low-Level Parasite Persistence Drives Vasculitis and Myositis in Skeletal Muscle of Mice Chronically Infected with Trypanosoma cruzi.

Authors:  Joseph D Weaver; Victoria J Hoffman; Ester Roffe; Philip M Murphy
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

3.  Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?

Authors:  Irene Losada Galván; Olaya Madrid Pascual; Juan María Herrero-Martínez; Ana Pérez-Ayala; Manuel Lizasoain Hernández
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

4.  Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease.

Authors:  Christopher A Seid; Kathryn M Jones; Jeroen Pollet; Brian Keegan; Elissa Hudspeth; Molly Hammond; Junfei Wei; C Patrick McAtee; Leroy Versteeg; Amanda Gutierrez; Zhuyun Liu; Bin Zhan; Jonathan L Respress; Ulrich Strych; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-10-13       Impact factor: 3.452

5.  Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment.

Authors:  José A Pérez-Molina; Francesca Norman; Rogelio López-Vélez
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

6.  A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.

Authors:  Carylinda Serna; Joshua A Lara; Silas P Rodrigues; Alexandre F Marques; Igor C Almeida; Rosa A Maldonado
Journal:  Vaccine       Date:  2014-04-30       Impact factor: 3.641

7.  Population pharmacokinetics of benznidazole in adult patients with Chagas disease.

Authors:  D Soy; E Aldasoro; L Guerrero; E Posada; N Serret; T Mejía; J A Urbina; J Gascón
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

8.  Nitro/nitrosyl-ruthenium complexes are potent and selective anti-Trypanosoma cruzi agents causing autophagy and necrotic parasite death.

Authors:  Tanira M Bastos; Marília I F Barbosa; Monize M da Silva; José W da C Júnior; Cássio S Meira; Elisalva T Guimaraes; Javier Ellena; Diogo R M Moreira; Alzir A Batista; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 9.  Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects.

Authors:  Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Michael J Heffernan; Kathryn Jones; Jesus G Valenzuela; Shaden Kamhawi; Jaime Ortega; Samuel Ponce de Leon Rosales; Bruce Y Lee; Kristina M Bacon; Bernhard Fleischer; B T Slingsby; Miguel Betancourt Cravioto; Roberto Tapia-Conyer
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

10.  The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease.

Authors:  Miguel Górgolas; Ignacio Robles; Alfonso Cabello; Ramón Pérez-Tanoira; Concepción Pérez-Jorge Peremarch; Ricardo Fernández-Roblas; Frances Williams; José Manuel Ramos Rincón
Journal:  Pathog Glob Health       Date:  2013-04       Impact factor: 2.894
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.